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Glioblastoma (GBM) is a grade IV astrocytoma formed primarily from cancerous astrocytes and sustained by intense angiogenesis. GBM often causes
non-specific symptoms, creating difficulty for diagnosis. This study aimed to utilize machine learning techniques to provide an accurate one-year survival
prognosis for GBM patients using clinical and genomic data from the Chinese Glioma Genome Atlas. Logistic regression (LR), support vector machines
(SVM), random forest (RF), and ensemble models were used to identify and select predictors for GBM survival and to classify patients into those with an
overall survival (OS) of less than one year and one year or greater. With regards to overall survival, a significant (p < 0.05, n = 175) correlation was found
with age (negative), radiation treatment (positive), and chemotherapy treatment (positive). IDH1 mutation and 1p19q codeletion showed insignificant
correlation with OS in this dataset. This potentially implies that IDH1 mutation alone, although important in secondary GBM prognosis, is insignificant for
primary GBM prognosis. 1p19q codeletion also appeared to be insignificant for primary GBM prognosis when considered alone. The ensemble model
had the highest overall accuracy, achieving a mean AUC score of 0.644 and an F1 score of 0.799.
(left, image credit: Medium). Sample ROC curve. A receiver operating
characteristic (ROC) curve “plots the true positive rate (TPR) versus the false
positive rate (FPR) as a function of the model’s threshold.” “The threshold
represents the value above which a data point is considered in the positive class.”
(Medium). In this study, survival of 365 days or greater is considered a “positive”
classification while survival of less than 365 days is considered a “negative”
classification. The area under the curve (AUC) quantifies the model’s performance
as a metric between 0 (worse) and 1 (better). In the figure, the blue curve has a
higher AUC than the red curve and thus would be considered better performing.

OS correlation: Negative – age; Positive – radiation, chemo status
Figure 1 (left). Correlation analysis of clinical
factors. Pearson correlation r values were
determined for clinical factors in relation to each
other. All statistically insignificant r values are
shown as “0”. Significant positive correlation was
found between overall survival and radiation
treatment status, between overall survival and
chemotherapy treatment status, and between
radiation treatment status and chemotherapy
treatment status (n = 176, rcrit = 0.148, p < 0.05).
Significant negative correlation was found
between overall survival and age and between
age and IDH1 mutation status (n = 175, rcrit = –
0.148, p < 0.05).

LR, SVM classifiers tend to underfit the dataset

Genomic factors are significantly correlated with OS
(Selected graphs shown)

Underfitting indicates that the
model is not specific enough to
the training data.

RF classifier tends to overfit the dataset

Overfitting indicates that the
model is too specific to the
training data.

Underfitting of LR, SVM counteracts overfitting of RF in ensemble
classifier

Figure 2 (above). Survival probability vs time for high and low expression strata of DYX1C1-CCPG1 (above
left) and RP11-355I22.2 (above right). Survival probability was plotted against time for patients in equally sized
strata of high and low expression of the respective genes. DYX1C1-CCPG1 (above left) was negatively
correlated with overall survival (r = –0.297), and RP11-355I22.2 (above right) was positively correlated with
overall survival (r = 0.450) in the selected cohort. Time at which survival probability = 0.50 was analyzed for
statistical significance (p-values shown on graphs).

Ensemble classifier had the highest accuracy
Figure 7 (left). F1 and AUC scores for each
classifier. F1 (harmonic mean of precision and
recall; see below, credit: Medium) and AUC
scores for each classifier were calculated.
Population standard deviation was calculated for
each value among the five stratified folds for
each classifier.
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SUMMARY

Figures 3, 4, 5, 6 (top to bottom). Mean receiver operating characteristic curves. Mean receiver operating
characteristic curves were generated for LR (3). SVM (4), RF (5), and ensemble (6) models trained and tested
using stratified 5-fold cross validation. AUC scores are shown in the figure legends.

Age was negatively correlated with overall survival, while radiotherapy and
chemotherapy status were positively correlated with overall survival. The ensemble
classifier exhibited the highest accuracy compared to the LR, SVM, and RF classifiers
alone – the LR and SVM classifiers’ underfitting tendency appeared to counteract the
RF classifier’s overfitting tendency.
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